Bibliografias temáticas / Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden

Índice

  1. Artigos de revistas
  2. Teses / dissertações
  3. Capítulos de livros
  4. Trabalhos de conferências

Literatura científica selecionada sobre o tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"

Autor: Grafiati
Publicado: 14 de março de 2023
Última modificação: 31 de julho de 2025

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"

1

Minchom, Anna, Wei Yuan, Mateus Crespo, et al. "Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab." Journal for ImmunoTherapy of Cancer 8, no. 1 (2020): e000713. http://dx.doi.org/10.1136/jitc-2020-000713.

Texto completo da fonte
Resumo:
BackgroundThis case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge.Case presentationA 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of pembrolizumab. On rechallenge with pembrolizumab, further disease stability was achieved. Serial biopsies and analysis by immunohistochemistry and immunofluorescence demonstrated marked immune infiltration and documented the emergency of markers of immune exhaustion
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Mahadevan, Daruka, Li Ma, Kai Treuner, Jenna Wong, and Catherine Schnabel. "330 Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for immune checkpoint inhibitors." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A356. http://dx.doi.org/10.1136/jitc-2021-sitc2021.330.

Texto completo da fonte
Resumo:
BackgroundImmune checkpoint inhibitors (ICIs) have improved patient outcomes and are a new standard of care for treating a variety of cancers. Eligibility for ICIs is established through determination of tumor type and use of predictive biomarkers. PD-L1, microsatellite instability (MSI), and tumor mutation burden (TMB) are FDA-approved predictive biomarkers for ICI therapies. However, the validity of these biomarkers remains controversial, as studies have shown a failure to predict ICI response in many cancer types.1 2 The 92-gene assay (CancerTYPE ID) is a validated gene expression classifie
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Sokol, Ethan, Natalie Danziger, Dean Pavlick, et al. "Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study." Journal of Clinical Oncology 38, no. 15_suppl (2020): 3558. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3558.

Texto completo da fonte
Resumo:
3558 Background: Germline mutations in the STK11 ( LKB1) mTOR pathway gene are associated with Peutz-Jehger’s Syndrome and a variety of malignancies of variable clinical aggressiveness. Recent evidence also links STK11 inactivation with failure to benefit from anti-cancer immune checkpoint inhibitor (IO) therapy in NSCLC. Methods: Using hybrid capture based CGP on extracted tumor DNA and a published “somatic-germline-zygosity” SGZ data analysis algorithm on 212,470 samples of clinically advanced malignancies, we identified 103 (0.05%) STK11GCa inactivating base substitutions or indels. Tumor m
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Lujambio, Amaia. "The more (mutations), the better." Science Translational Medicine 11, no. 477 (2019): eaaw5320. http://dx.doi.org/10.1126/scitranslmed.aaw5320.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Hsiehchen, David, Magdalena Espinoza, Cristina Valero, Chul Ahn, and Luc G. T. Morris. "Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups." Journal for ImmunoTherapy of Cancer 9, no. 11 (2021): e003683. http://dx.doi.org/10.1136/jitc-2021-003683.

Texto completo da fonte
Resumo:
The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden (TMB) of at least 10 mut/Mb is postulated to reduce healthcare disparities by broadly expanding treatment eligibility. In a cohort of 39,400 patients with available genomic and race data, black and Asian patients were less likely to have TMB-high cancers in multiple types of malignancies based on the currently approved cut-off. Decreasing TMB thresholds preferentially increased the eligibility of minority patients for immune checkpoint inhibitors while retaining predictive value of treatment benefit in a co
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Pavlov, A. Yu, A. G. Dzidzaria, R. A. Gafanov, et al. "Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors." Cancer Urology 20, no. 1 (2024): 153–63. http://dx.doi.org/10.17650/1726-9776-2024-20-1-153-163.

Texto completo da fonte
Resumo:
Therapeutic landscape of several genitourinary malignancies has been revolutionized by the development of immune checkpoint inhibitors; however, the utility of immunotherapies in prostate cancer has been limited, partly due to the immunologically “cold” tumor microenvironment of prostate cancer. As of today, pembrolizumab is the only immune checkpoint inhibitor approved for treatment of metastatic castration-resistant prostate cancer (mCRPC) in a select group of patients with high microsatellite instability, deficient mismatch repair, or high tumor mutational burden. Currently, several combina
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Barroso-Sousa, Romualdo, Jana Priscila Pacífico, Sarah Sammons, and Sara M. Tolaney. "Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities." Cancers 15, no. 15 (2023): 3997. http://dx.doi.org/10.3390/cancers15153997.

Texto completo da fonte
Resumo:
Tumor mutational burden (TMB) correlates with tumor neoantigen burden, T cell infiltration, and response to immune checkpoint inhibitors in many solid tumor types. Based on data from the phase II KEYNOTE-158 study, the anti-PD-1 antibody pembrolizumab was granted approval for treating patients with advanced solid tumors and TMB ≥ 10 mutations per megabase. However, this trial did not include any patients with metastatic breast cancer; thus, several questions remain unanswered about the true role of TMB as a predictive biomarker of benefit to immune checkpoint inhibitor therapy in breast cancer
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

An, Ho Jung, Hong Jae Chon, and Chan Kim. "Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors." International Journal of Molecular Sciences 22, no. 17 (2021): 9414. http://dx.doi.org/10.3390/ijms22179414.

Texto completo da fonte
Resumo:
As cancer immunotherapy using immune checkpoint inhibitors (ICIs) is rapidly evolving in clinical practice, it is necessary to identify biomarkers that will allow the selection of cancer patients who will benefit most or least from ICIs and to longitudinally monitor patients’ immune responses during treatment. Various peripheral blood-based immune biomarkers are being identified with recent advances in high-throughput multiplexed analytical technologies. The identification of these biomarkers, which can be easily detected in blood samples using non-invasive and repeatable methods, will contrib
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Albertí-Valls, Manel, Sara Olave, Anna Olomí, Anna Macià, and Núria Eritja. "Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment." Cancers 16, no. 23 (2024): 3918. http://dx.doi.org/10.3390/cancers16233918.

Texto completo da fonte
Resumo:
Endometrial cancer is one of the most common gynecological malignancies, and while early-stage cases are highly treatable, recurrent or advanced EC remains challenging to manage. Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized treatment approaches in oncology, and its application in EC has shown promising results. Key to immunotherapy efficacy in EC is the tumor’s mismatch repair status, with MMR-deficient tumors demonstrating a higher tumor mutational burden and increased PD-L1 expression, making them more susceptible to immune checkpoint inhibitors (ICIs) such as
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Smith, Katherine E. R., and Svetomir N. Markovic. "Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors." Clinical Chemistry 70, no. 1 (2024): 25–26. http://dx.doi.org/10.1093/clinchem/hvad128.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Mais fontes

Teses / dissertações sobre o assunto "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"

1

Daffinà, Maria Grazia. "PREDICTIVE BIOMARKER OF LONG TERM SURVIVAL IN MESOTHELIOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS." Doctoral thesis, Università di Siena, 2021. http://hdl.handle.net/11365/1160848.

Texto completo da fonte
Resumo:
Background: Targeting immune-checkpoint inhibitors (ICIs) has proven effective in a variety of tumor types. Primary and secondary resistance to treatment is emerging as a major limitation of ICIs therapy, but little data are available on efficacy of re-treatment in immune checkpoint blockade (ICB)-resistant subjects. The identification of biomarkers predictive of response to ICI and re-treatment of ICI-resistant patients are currently under investigations as promising tools in clinical practice. Aim of this study is to evaluate the efficacy, safety and clinical activity of re-treatment with
Estilos ABNT, Harvard, Vancouver, APA, etc.

Capítulos de livros sobre o assunto "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"

1

Emancipator, Kenneth, Jianda Yuan, Razvan Cristescu, Deepti Aurora-Garg, and Priti S. Hegde. "Predictive Biomarkers (Programmed Death Ligand 1 Expression, Microsatellite Instability, and Tumor Mutational Burden) for Response to Immune Checkpoint Inhibitors." In Cancer Immunotherapy Principles and Practice, 2nd ed. Springer Publishing Company, 2021. http://dx.doi.org/10.1891/9780826137432.0045.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.

Trabalhos de conferências sobre o assunto "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"

1

Sousa, Romualdo Barroso, Svitlana Tyekucheva, Pedro Exman, et al. "TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1g04.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Hsieh, Yi-Lin, Pei-Ning Yu, Yi-Hua Jan, et al. "Abstract 3177: Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3177.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Hu, Jing, Bixun Li, Bing Zou, et al. "Abstract 620: Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-620.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Barroso-Sousa, R., S. Tyekucheva, S. Pernas-Simon, et al. "Abstract P5-12-02:PTENalterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p5-12-02.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Você também pode estar interessado nas extensas listas de trabalhos sobre o assunto "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden":
Artigos de revistas
Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!

Vá para a bibliografia